Some thoughts on the $IPIX 8k and the notes from a couple
Some thoughts on the $IPIX 8k and the notes from a couple of posters who attended the $IPIX shareholder meeting:
- There were 150M YES vs 14M NO votes on the authorized share increase. That represents more than a 10 to 1 ratio. This validates that a very large majority of $IPIX shares are STRONGLY held by investors that believe in $IPIX science and trust Leo to continue to wisely manage financial resources of stock issuance required for $IPIX science advancement.
- It is and will be very telling if $IPIX share price continues to be compressed. With 150M+ shares strongly held, where will the sellers come from? Does anyone believe that shareholders that voted YES will sell their shares for pennies or is it more likely that they are hanging on longer term for dollars? Typically you need to have both a seller and a buyer to make a transaction. I believe we will see a lot of “volume” without a lot of sellers. How is that logically possible?……..hmm UNLESS they are not real transactions! There will likely be more counterfeit shares with bogus transactions as the NSS/NR/criminals keep digging themselves into a deeper hole. I am also guessing that some of the investors that make up the 150M share count that are STRONG & LONG will take advantage of some additional bargain hunting courtesy of the criminals.
- B-OM phase 3 guidelines are for 300 active drug recipients. + 150 placebo which is set up to be a very favorable trial for streamlined advancement. It only takes 1 of the several interested parties to finalize a deal. Note that $IPIX is not jumping into any trials without first securing non-dilutive financing to fund that particular trial. A B-OM partnership could be inked without warning at which time a relatively short B-OM phase3 trial will quickly commence.
- My favorite quote from a shareholder note from Dr. Bertolino regarding B-IBD pill was “BP wants to see a 2a. BP told them that if they can show them a successful 2a, they will be “knocking their door down“. If that quote doesn’t get you extremely excited about $IPIX, you probably shouldn’t be invested in biotech IMO. Dr. Bertolino also was quoted: “Dr. B spoke up and said, “I’m still here after 3 years, and if I didn’t believe, I wouldn’t be here anymore.”
- Another great quote: “Leo said that he will provide more clarity in the coming weeks. “A new direction, a new understanding of what’s going on, actually growing the company, not shrinking it.” I personally believe Leo is more than just a fiscally prudent CEO. I believe he will execute a well thought out plan and that no one not named Leo or Arthur will be able to predict the exact WHAT or the exact WHEN. Long term investors will want to have maximum exposure as this plan unfolds and the science progresses.
- IMO the Alfasigma deal was the foundation for the Brilacidin franchise. Having a partner fund trials to advance and further validate the science is huge. I personally believe this was a great milestone regardless of whatever upfront cash $IPIX ended up with in the deal. The Right of First Refusal is financially a good floor for future IBD instance negotiation but this contractual feature strongly favors $IPIX to maximize Brilacidin IBD monetization.
- Per the POS AM financial filing it appears that Outstanding Share count will rise from 205,620,200 up to approximately 262,535,967. I am personally more than OK with a share count under 300M shares as IPIX enters multiple instances in mult-billion dollar markets. B-OM phase 3 costs will be paid for by a B-OM future partner. B-IBD UP/UPS is being paid for by Alfasigma. B-IBD Colitis will be paid for by whatever BP partner ‘knocks the door down” to grab a big chunk of a $48B market. We may see some type of Kevetrin partnership down the road but in the meantime IPIX will use some resources to advance Kevetrin pill form which if successful will make $IPIX shareholders very wealthy IMO.
Summary:
$IPIX continues to advance their science with frugal management of resources. The Alfasigma deal is the foundation for the Brilacidin franchise. The announced B-IBD pill development with BDD is a huge strategic initiative that positions IPIX in an extremely lucrative IBD colitis market. B-OM is a phase 3 ready instance with multiple parties engaged in partnership discussions with a clearly defined and detailed roadmap paved in cooperation with the FDA. $IPIX is positioned in the EU for trial advancement and eventual distribution.
$IPIX short term share price will continue to be artificially compressed as the criminals have no good option other than to continue to pump out additional counterfeit shares. The NSS crews and SMB bashers are out in full force. The problem for them though is that a vast majority of $IPIX shareholders are Real Longs who are holding and in many cases buying more shares to increase their position and to lower their cost basis. As $IPIX continues to advance the science and as Leo executes strategies and achieves milestones, there will be a pendulum swing in the control of $IPIX share price. The criminals at some point will be forced to try to do a controlled take up. They may or may not be able to control their targeted prices in hopes of shorting them back down. If the 150M share base of LONG & STRONG are right about Leo’s ability to execute and new investors flood into $IPIX stock, then we will be looking at an entirely different situation as far as who is in control and who gets crushed.
21
2
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...
Continue Reading
Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...
Continue Reading
The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...
Continue Reading
Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...
Continue Reading
IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...
Continue Reading
Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...
Continue Reading
The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...
Continue Reading
Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...
Continue Reading
In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...
Continue Reading
Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...
Continue Reading
Top 5 Most Recently Viewed Articles
Monument Real Estate Services Enhances Efficiency with Funnel Monument Real Estate Services (MRES) is making significant strides in enhancing operational efficiency and improving the experience for both renters and employees. They've partnered with Funnel, an innovative player known for its AI-powered Customer Relationship Management (CRM) solutions tailored specifically...
Continue Reading
Enhancing Home Value: Spring Improvements for Sellers As homeowners consider putting their property on the market, leveraging the spring season presents an excellent opportunity to enhance their home's appeal. The warmer weather opens doors for various projects that can significantly influence potential buyers' perceptions, ultimately leading to increased value and faster...
Continue Reading
iCRYO to Attend Gala Promoting Health and Wellness Initiatives iCRYO, recognized as a leading name in the realm of whole-body wellness and longevity, is excited to announce its participation in the MAHA Spring Gala. This important event, hosted by MAHA Action, will take place soon and aims to unite esteemed guests devoted to improving health and well-being across the...
Continue Reading
Integral Ad Science Holding Corp. (IAS) Class Action Lawsuit Integral Ad Science Holding Corp. (NASDAQ: IAS) is facing significant scrutiny as law firms encourage investors who may have suffered losses to take action. The Law Offices of Howard G. Smith have announced a class action lawsuit on behalf of those who purchased IAS common stock during specific periods in the...
Continue Reading
DAQQ New Energy Corp Reaches New Stock Heights In a standout achievement for DAQQ New Energy Corp, its stock price has surged to a remarkable 52-week peak of $30.04. This impressive milestone not only highlights the company's growth trajectory but also reflects a robust 14.44% increase over the past year. Such performance indicates heightened investor confidence in DAQQ...
Continue Reading